Cinven bought Eurovita bonds from GIC, others to help liquidation-source

<html xmlns=""><head><title>RPT-UPDATE 1-Cinven bought Eurovita bonds from GIC, others to help liquidation-source</title></head><body>

Adds dropped word in paragraph 11

Italian prosecutors investigating Eurovita crisis

Cinven's position improves if liquidation is orderly

First Italian insurance to go into special administration

By Valentina Za and Emilio Parodi

MILAN, Sept 27 (Reuters) -Private equity firm Cinven has agreed to buy back 160 million euros ($170 million) of debt sold by its insurer Eurovita and is open to supporting other measures to avoid a messy liquidation of the Italian company, a person with knowledge of the situation told Reuters.

Cinven this month signed an accord with GIC, Singapore's sovereign fund, and another two investors to purchase from them 140 million euros of Tier2 Eurovita bonds, the source added.

GIC and Eurovita had no comment.

Cinven, which acquired Eurovita in 2017, also launched a tender offer to buy back another 20 million euros of bonds from investors including Italian financial institutions, so that only around 9 million remain outstanding, the source said.

The tender bid'sdocument shows showed a vehicle owned by Cinven offered 350 euros to repurchase 1,000 euros worth of bonds, with a 65% discount to the nominal value.

The offer aims to "to offer liquidity to holders and to assist in ensuring an orderly resolution of the issuer's liabilities," the document said.

Italian insurance authorities placed Eurovita under special administration this year, the first time they have taken such a step, after rising rates blew a hole in the life insurer's cash reserves.

At one point, Eurovita's capital needs were at least four times higher than what Cinven had put in to try and plug the shortfall, another person with knowledge of the matter told Reuters at the time.

To protect savers, a group of five insurers has agreed to take over the life policies of Eurovita clients, while the rest of the company will be liquidated, in a rescue orchestrated by Italian authorities. The five insurers will become shareholders in a new company dubbed Cronos Vita.

Italian prosecutors have been probing false accounting charges in relation to the blow-up.

Cinven's efforts to stave off an insolvent liquidation, in which a company is forced to sell its assets to repay creditors, would improve its position in relation to the criminal inquiry, another person close to the matter said.

The British investment firm had offered to pump 100 million euros into the new Cronos Vita company, the two sources said, matching a cash injection into Eurovita it conducted in February following pressure from regulators.

Instead, Cinven was asked to carry out the debt buyback and cancel the bonds to support a solvent liquidation, one of the people added.
Like other life insurers, especially those relying on banks to sell products, Eurovita was hit by early redemptions once rates started rising and savers sought better returns.

News of the firm's troubles and Cinven's reluctance to promptly run to the rescue accelerated redemptions, eventually forcing regulators to halt them.

The freezing is in place until Oct. 31 when the new company is expected to be established.

Assicurazioni Generali GASI.MI, PosteVita PST.MI, Intesa Sanpaolo Vita ISP.MI, UnipolSAI US.MI, as well as Germany's Allianz ALVG.DE, in June agreed to take over Eurovita policies.

Contrary to the initial scheme, Allianz is taking 10% and not 20%, with the other four filling the gap, two people close to the matter said. The insurers involved declined to comment.

($1 = 0.9437 euros)

Reporting by Valentina Za and Emilio Parodi; Editing by Josie Kao


Avertissement : Les entités de XM Group proposent à notre plateforme de trading en ligne un service d'exécution uniquement, autorisant une personne à consulter et/ou à utiliser le contenu disponible sur ou via le site internet, qui n'a pas pour but de modifier ou d'élargir cette situation. De tels accès et utilisation sont toujours soumis aux : (i) Conditions générales ; (ii) Avertissements sur les risques et (iii) Avertissement complet. Un tel contenu n'est par conséquent fourni que pour information générale. En particulier, sachez que les contenus de notre plateforme de trading en ligne ne sont ni une sollicitation ni une offre de participation à toute transaction sur les marchés financiers. Le trading sur les marchés financiers implique un niveau significatif de risques pour votre capital.

Tout le matériel publié dans notre Centre de trading en ligne est destiné à des fins de formation / d'information uniquement et ne contient pas – et ne doit pas être considéré comme contenant – des conseils et recommandations en matière de finance, de fiscalité des investissements ou de trading, ou un enregistrement de nos prix de trading ou une offre, une sollicitation, une transaction à propos de tout instrument financier ou bien des promotions financières non sollicitées à votre égard.

Tout contenu tiers, de même que le contenu préparé par XM, tels que les opinions, actualités, études, analyses, prix, autres informations ou liens vers des sites tiers contenus sur ce site internet sont fournis "tels quels", comme commentaires généraux sur le marché et ne constituent pas des conseils en investissement. Dans la mesure où tout contenu est considéré comme de la recherche en investissement, vous devez noter et accepter que le contenu n'a pas été conçu ni préparé conformément aux exigences légales visant à promouvoir l'indépendance de la recherche en investissement et, en tant que tel, il serait considéré comme une communication marketing selon les lois et réglementations applicables. Veuillez vous assurer que vous avez lu et compris notre Avis sur la recherche en investissement non indépendante et notre avertissement sur les risques concernant les informations susdites, qui peuvent consultés ici.

Nous utilisons des cookies pour vous donner la meilleure expérience possible de notre site internet. En savoir plus ou modifier vos paramètres de cookies.

Avertissement sur les risques : votre capital est à risque. Les produits à effet de levier ne sont pas recommandés pour tous. Veuillez consulter notre Divulgation des risques